Ellipses Pharma
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | RETSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | FLT3 / Aurora kinase A and BSmall molecule | Acute Myeloid Leukemia | |
| Phase 1/2 | Androgen receptor (selective)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12-31 · NCT05265091 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
December 2027 (1)
MobinitinibPhase 1/2Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Est. primary completion 2027-12 · NCT04581512 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
VosilasarmPhase 1/2Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.